INTERNATIONAL ISOTOPES INC
NT 10-K, 1999-04-01
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: THURLOW FUNDS INC, 497, 1999-04-01
Next: KENDLE INTERNATIONAL INC, S-8, 1999-04-01



                                  UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                              WASHINGTON, DC 20549



(Check One): [X]Form 10-K [ ]Form 20-F [ ]Form 11-K  [ ]Form 10-Q [ ]Form N-SAR

         For Period Ended: December 31, 1998 
         [ ] Transition Report on Form 10-K
         [ ] Transition Report on Form 20-F 
         [ ] Transition Report on Form 11-K 
         [ ] Transition Report on Form 10-Q 
         [ ] Transition Report on Form N-SAR

         For the transition Period Ended : _____________________________

- -------------------------------------------------------------------------------
  Read Instruction (on back page) before Preparing Form. Please Print or Type.
    Nothing in this form shall be construed to imply that the Commission has
                   Verified any information contained herein.
- -------------------------------------------------------------------------------

If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

INTERNATIONAL ISOTOPES, INC.
Full Name of Registrant:

Former Name if Applicable

3100 JIM CHRISTAL RD.
Address of Principal Executive Office (Street and Number)

DENTON, TX  76207
City, State and Zip Code

PART II - Rules 12b-25(b) AND (c)

If the subject report could not be filed without reasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate) 

       (a) The reasons described in reasonable detail in Part III of this form
           could not be eliminated without unreasonable effort or expense; 

       (b) The subject annual report, semi-annual report, transition report of
           Form 10-K, Form 20-F, 11-K, Form N-SAR, or portion thereof, will be
           filed on or before the fifteenth calendar day following the
[X]        prescribed due date; or the subject quarterly report of transition
           report of Form 10-Q, or portion thereof will be filed on or before
           the fifth calendar day following the prescribed due date; and 

       (c) The accountant's statement or other exhibit required by Rule12b-25(c)
           has been attached if applicable.

<PAGE>

PART III - NARRATIVE

State below in reasonable detail the reason why the Form 10-K, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof, could not be filed within
the prescribed time period. (Attach Extra Sheets if Needed)

The Company is in the process of completing negotiations for private equity
funding and debt repayment that it believes will resolve certain liquidity
issues and will cause the 10-K to more accurately reflect the current financial
condition of the Company.

These negotiations could not be completed by March 31, 1999 without unreasonable
effort and expense.

There can be no assurance, however, that these transactions will be completed.


PART IV - OTHER INFORMATION

(1)   Name and telephone number or person to contact in regard to this 
      notification

           Joan Gillett                    940              484-9492     
           ------------                -----------     ------------------
              (Name)                   (Area Code)     (Telephone Number)

(2)  Have all other periodic reports required under Section 13 or 15(d) of the
     Securities Exchange Act of 1934 or Section 30 or the Investment Company Act
     of 1940 during the preceding 12 months or for such shorter period that the
     registrant was required to file such report(s) been filled? If answer is
     no, identify report(s).      [X] Yes   [ ] No
- -------------------------------------------------------------------------------

(3)  Is it anticipated that any significant change in results of operations from
     the corresponding period for the last fiscal year will be reflected by the
     earnings statement to be included in the subject report or portion thereof?
                                  [ ] Yes   [X] No

If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

- -------------------------------------------------------------------------------

                          INTERNATIONAL ISOTOPES, INC.
                  (Name of registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned 
hereunto duly authorized

March 31, 1999              By:/s/ Ira Lon Morgan, Ph.D.
                            ----------------------------
                            Ira Lon Morgan, Ph.D.
                            Chairman & Treasurer


INSTRUCTIONS: The form may be signed by an executive officer of the registrant
or by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive office), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.

- -------------------------------------------------------------------------------
                                    ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal 
Violations (See 18 U.S.C. 1001).
- -------------------------------------------------------------------------------



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission